A correction to a previously published study involving MOTS-c was issued on September 9, 2026. The correction pertains to the paper titled "Correction: Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction." It was published in the journal Scientific Reports.
This entry represents a correction notice tied to the original publication, as indexed on PubMed under record ID 42716952. The event data does not specify what aspect of the original paper was corrected or the nature of the change. No findings, results, or conclusions from the underlying study are detailed in this correction notice.
MOTS-c remains classified as an unapproved compound used only in research settings. This publication update does not constitute new research findings and should not be interpreted as evidence of efficacy or safety. Readers interested in the broader context of MOTS-c research can consult the compound overview for additional background.